Skip to main content
Article
Tolerability of Induction Chemotherapy Dosing Practices in Acute Myeloid Leukemia Patients
Leukemia Research
  • Kaylene M. Peric
  • David J. Reeves, Butler University
Document Type
Article
Publication Date
1-1-2015
DOI
http://dx.doi.org/10.1016/j.leukres.2014.11.024
Abstract
For patients with high body surface areas (BSA), differing chemotherapy dosing strategies have been utilized in attempts to reduce toxicity. In a retrospective evaluation, we compared the effects of chemotherapy dosing in acute myeloid leukemia patients with high BSA (>2 m2) who received capped doses (n = 12) to those who received uncapped doses (n = 24), and to patients with BSA ≤ 2 m2 (n = 42). There were no statistically significant differences among groups (BSA ≤ 2 m2, BSA > 2 m2 capped, and BSA > 2 m2 uncapped) in the incidences of febrile neutropenia (85.7, 66.7, and 75.0%, respectively, p = 0.29), bacteremia (19.0, 8.3, and 16.7%, respectively, p = 0.68), mucositis (42.8, 50.0, and 41.7%, respectively, p = 0.88) or nausea/vomiting (47.6, 33.3, and 37.5, respectively, p = 0.57). Results suggest delivery of unadjusted chemotherapy based on actual body weight is likely safe in hematological malignancies.
Rights

© Elsevier 2015. This post-print version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/.

Citation Information
Kaylene M. Peric and David J. Reeves. "Tolerability of Induction Chemotherapy Dosing Practices in Acute Myeloid Leukemia Patients" Leukemia Research Vol. 39 Iss. 2 (2015) p. 173 - 176
Available at: http://works.bepress.com/david-reeves/11/